Jiangsu HengRui Medicine Co.
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Jiangsu HengRui Medicine Co. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Jiangsu HengRui Medicine Co.: 8 sponsored US clinical trials, 2 recruiting.
Jiangsu HengRui Medicine Co. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced or Metastatic and Unresectable HCC, with 1 trials.
Upper-quartile sponsor footprint
Jiangsu HengRui Medicine Co. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
NCT07286032
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
NCT05277168
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
NCT04663282
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
NCT04447118
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
NCT04446260
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
NCT03764293
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03463187
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 4 |
What is open in the Jiangsu HengRui Medicine Co. pipeline
2 recruiting of 8 indexed (25% open); 5 completed (63%).
Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Locally Advanced or Metastatic and Unresectable HCC (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jiangsu HengRui Medicine Co.: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Jiangsu HengRui Medicine Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Jiangsu HengRui Medicine Co. page
8 registered trials is a research-attention snapshot, not an endorsement of Jiangsu HengRui Medicine Co. or any single study.
- 2 of Jiangsu HengRui Medicine Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Locally Advanced or Metastatic and Unresectable HCC is the condition Jiangsu HengRui Medicine Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced or Metastatic and Unresectable HCC trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jiangsu HengRui Medicine Co. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.